Bristol Myers Squibb has entered into a significant agreement valued at up to $15.2 billion with Jiangsu Hengrui Medicine, the top pharmaceutical firm in China by market value. This partnership includes 13 early-stage drug programs spanning oncology, hematology, and immunology, none of which have yet commenced human clinical trials. The announcement coincided with Bristol Myers Squibb facing critical patent expirations, prompting the strategic collaboration.
Back
